X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2%
Mon, 30 Jul

NOVARTIS has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:

NOVARTIS Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-17*
3
Mar-18*
3
Jun-18*
QoQ ChangeYoY Change
Net SalesRs m1,1481,2531,38110.2%20.3%
Other incomeRs m2271,096223-79.7%-1.8%
TurnoverRs m1,3752,3491,604-31.7%16.6%
ExpensesRs m1,2691,4721,416-3.8%11.6%
Gross profitRs m-121-219-35
DepreciationRs m7673.1%-7.0%
InterestRs m05115-70.2%7550.0%
Profit before taxRs m99819166-79.7%68.4%
TaxRs m2855566-88.1%133.7%
Profit after taxRs m70265100-62.2%42.2%
Gross profit margin%-10.5-17.5-2.5
Effective tax rate%28.667.739.7
Net profit margin%5.111.36.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 20.3% on a year-on-year (YoY) basis. The expenses were up by 11.6% YoY during the same period.
  • The company's operating profit declined by 71.1% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 2.5% in 1QFY19 as against 10.5% in 1QFY18.
  • Depreciation charges and finance costs declined by 7.0% YoY and 7550.0% YoY, respectively.
  • Other income declined by 1.8% YoY during the quarter.
  • Net profit for the quarter increased by 42.2% YoY. Net profit margins during the quarter increased from 5.1% in 1QFY18 to 6.2% in 1QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 10.2% on a quarter-on-quarter (QoQ) basis. The expenses were down by 3.8% QoQ during the same period.
  • The company's operating profit increased by 84.0% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 2.5% in 1QFY19 as against 17.5% in 4QFY18.
  • Net profit for the quarter declined by 62.2% QoQ, while net profit margins declined from 11.3% in 4QFY18 to 6.2% in 1QFY19.

To see how NOVARTIS has performed over the last eight quarters, please visit here.

NOVARTIS Share Price Performance

Over the last one year, NOVARTIS share price has moved up from Rs 629.9 to Rs 634.2, registering a Gain of Rs 4.3 or around 0.7%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,122.7 (up 0.7%). Over the last one year it has moved down from 14,414.2 to 14,122.7, a gain of 291 points (down 2.0%).

Overall, the S&P BSE SENSEX is up 0.4% over the year.

Current Valuations

At the current price of Rs 634.2, the price to earnings (P/E) ratio of NOVARTIS stands at 261.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 29.0 times.

Equitymaster requests your view! Post a comment on "NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2%". Click here!

  

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 16, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ALEMBIC PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS